Organogenesis Hldgs Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $109.976M Beat $101.050M Estimate
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is unchanged from the same period last year
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q1 Revenue $110M, Vs. Street Est of $101.1M
04:31 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q1 Revenue $110M, vs. Street Est of $101.1M
Organogenesis | 10-Q: Quarterly report
Organogenesis Holdings 1Q Loss $2.1M >ORGO
Organogenesis Holdings 1Q Loss $2.1M >ORGO
Press Release: Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine co
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint.
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint.
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six monthsTransformational opportunity for Organogenesis to ent
Insider Sellers Might Regret Selling Organogenesis Holdings Shares at a Lower Price Than Current Market Value
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) stock price has dropped 20% in the previous week, but insiders who sold US$941k in stock over the past year have had less luck. Given that the average sell
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates.Caterpillar reported a first
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) s
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Organogenesis Cleared of Claims by US District Court
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
Earnings Call Summary | Organogenesis(ORGO.US) Q4 2023 Earnings Conference
The following is a summary of the Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript:Financial Performance:Organogenesis reported Q4 net revenue of $99.7 million, a decrease of 14% y
Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) P/E Is On The Mark
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Organogenesis Holdings Inc. (NASDAQ:ORGO) as a stock to avoid entirely with
Organogenesis Holdings Full Year 2023 Earnings: Misses Expectations
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript
Why Organogenesis Holding Stock Plummeted by 18% Today
No Data